A5049409607- Hepatitis B Virus Studies
- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
First People's Hospital of Yunnan Province
2024-2025
Kunming University of Science and Technology
2024-2025
Although nucleotide analogs (NAs) and interferons are currently the primary treatments for chronic hepatitis B, they do not entirely remove cccDNA from hepatocytes. Antiviral therapy's desired outcome is absence of B surface antigen(HBsAg), often known as a clinical cure. interferon therapy has significantly higher HBsAg clearance serologic conversion rates than NAs, combination or sequential can improve to some extent. Still, only small proportion patients will achieve As result, it...
<title>Abstract</title> <bold>Background and Aims: </bold>Chronic hepatitis B (CHB) is a major global health concern. This study aims to investigate the factors influencing surface antigen (HBsAg) clearance in CHB patients treated with pegylated interferon α-2b (Peg-IFNα-2b) for 48 weeks establish predictive model. <bold>Methods: </bold>This analysis based on "OASIS" project, prospective real-world multicenter China. We included who completed of Peg-IFNα-2b treatment. Patients <bold>were...
Abstract Background and Aims Chronic hepatitis B (CHB) is a major global health concern. This study aims to investigate the factors influencing surface antigen (HBsAg) clearance in CHB patients treated with pegylated interferon α-2b (Peg-IFNα-2b) for 48 weeks establish predictive model. Methods analysis based on “OASIS” project, prospective real-world multicenter China. We included who completed of Peg-IFNα-2b treatment. Patients were randomly assigned training set validation ratio...